Cetuximab is given by intravenous therapy and costs up to $30,000 for eight weeks of treatment per patient.[19]
Merck KGaA had 887 million euros ($1.15 billion) in Erbitux sales in 2012, from head and neck as well as bowel cancer, while Bristol-Myers Squibb generated $702 million in sales from the drug.[20]
Erbitux was the eighth best-selling cancer drug of 2013, with sales of $1.87 billion.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)